Neutral





Jyothy Laboratories

—

Bloomberg	JYL IN
Equity Shares (m)	367
M.Cap.(INRb)/(USDb)	55.4 / 0.7
52-Week Range (INR)	187 / 130
1, 6, 12 Rel. Per (%)	0/7/-4
12M Avg Val (INR M)	102

Financials & Valuations (INR b)

	- 1	- 1	
Y/E March	2022	2023E	2024E
Net Sales	22.0	24.4	26.5
Sales Gr. (%)	15.1	11.0	8.9
EBITDA	2.5	3.0	3.7
EBITDA Margins (%)	11.3	12.5	13.8
Adj PAT	1.6	1.9	2.3
Adj.EPS (INR)	4.3	5.1	6.3
EPS Gr. (%)	-25.7	18.3	23.2
BV/Sh (INR)	39.3	40.9	42.4
Ratios			
RoE (%)	11.1	12.8	15.2
RoCE (%)	10.8	12.5	15.0
Payout (%)	69.8	70.8	76.6
Valuation			
P/E (x)	34.8	29.4	23.9
P/BV (x)	3.8	3.7	3.6
EV/EBITDA	22.0	17.6	14.3
Div. Yield (%)	1.7	2.0	2.7

Shareholding pattern (%)

As On	Mar-22	Dec-21	Mar-21
Promoter	62.9	62.9	62.9
DII	16.9	18.3	16.9
FII	II 10.9		12.5
Others	9.3	8.9	7.8

FII Includes depository receipts

Material cost pressures continue

CMP: INR151

 Sales in 4QFY22 were in line. Gross margin was affected due to elevated raw material prices. The impact was reflected in EBITDA margin, which stood at 10.6% (est. 12%).

TP: INR150

- Revenue growth is key for a company with sales of only ~INR22b. The likelihood of a consistent 15% sales growth (essential for any re-rating) continues to appear difficult, despite JYL's efforts to ramp up its total and direct reach. Sales CAGR have been a tepid at 5.5% for the preceding five years ending FY22.
- With margin likely to remain under pressure over the next few quarters due to high input costs, its earnings growth prospects remain weak. We maintain our **Neutral** rating.

In line result, RM cost pressure led to a contraction in gross margin

- Standalone net sales grew 10.3% YoY to ~INR5.4b (in line).
- EBITDA declined by 18.6% YoY to INR568m (est. INR630m).
- PBT declined by 18% YoY to INR437m (in line).
- Adjusted PAT declined by 23.7% YoY to INR385m (in line).
- Gross margin contracted by 500bp YoY (-100bp QoQ) to 40.1%. As a percentage of sales, lower ad spends/staff cost/other expenses at 7.2%/ 10.6%/11.7% (-60bp/-20bp/-50bp YoY) led to a 380bp contraction in EBITDA margin to 10.6% (an eight quarter low).
- Sales grew 15%, while EBITDA/adjusted PAT fell ~21%/27% YoY in FY22.
- Consolidated segmental performance: Fabric Care/Dishwashing/ Household Insecticides/Personal Care grew ~17.9%/12.2%/-9.1%/11.7% YoY to INR2.1b/INR1.9b/INR793m/INR467m in 4QFY22.

Highlights from the management commentary

- JYL has taken various price hikes in the range of 6-7% and has also reduced grammage. It has also taken a minor price increase in Apr'22.
- Volume growth stood at 3.6%/9% in 4Q/FY22.
- There is a marginal decline in rural demand (40% of JYL's sales accrues from the rural market). The management expects potential rural offtake recovery on the back of a good monsoon.

Valuation and view

- We lower our FY23 EPS estimate by 7.9% on continued raw material pressure and our FY24 EPS estimate by less than 2%.
- For a company that has a far lower sales base of INR21.9b in FY22 (v/s its peers), its performance over the past five years has been consistently lackluster (at 5.5%/-0.5% sales/operating profit CAGR).
- RoCE, at 11% in FY22, remains far inferior v/s its peers. No marked uptick is visible over the medium term. We assign a 15x EV/EBITDA target multiple to our Mar'24E target, resulting in a TP of INR150 per share. We maintain our Neutral rating.

Krishnan Sambamoorthy - Research analyst (Krishnan.Sambamoorthy@MotilalOswal.com)

Research analyst: Kaiwan Jal Olia (Kaiwan.O@MotilalOswal.com) | Aditya Kasat (Aditya.Kasat@MotilalOswal.com)

 $Motilal\ Oswal$ Jyothy Laboratories

Standalone quarterly performa	ance											(INR m)
Y/E March		FY21				FY22					FY22E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	FY21	FY22	4QE	(%)
Net Sales	4,287	4,996	4,694	4,873	5,219	5,783	5,287	5,374	18,850	21,663	5,255	2.3
YoY change (%)	4.1	7.6	15.3	27.5	21.8	15.7	12.6	10.3	13.2	14.9	7.8	
Gross Profit	1,968	2,373	2,269	2,197	2,250	2,296	2,170	2,154	8,807	8,869	2,283	-5.6
Margin (%)	45.9	47.5	48.3	45.1	43.1	39.7	41.0	40.1	46.7	40.9	43.4	
EBITDA	782	889	798	698	650	671	605	568	3,167	2,495	630	-9.8
EBITDA growth %	19.4	12.4	22.6	73.9	-16.9	-24.5	-24.2	-18.6	26.8	-21.2	-9.8	
Margin (%)	18.3	17.8	17.0	14.3	12.5	11.6	11.4	10.6	16.8	11.5	12.0	
Depreciation	187	193	198	200	206	206	210	164	779	785	212	
Interest	51	29	20	18	17	18	18	14	117	67	15	
Other Income	42	39	63	53	48	52	43	46	198	190	47	
PBT	587	706	643	533	476	500	420	437	2,469	1,832	451	-3.1
Tax	83	100	121	28	75	79	66	52	332	271	76	
Rate (%)	14.1	14.1	18.8	5.3	15.7	15.7	15.7	11.8	13.4	14.8	16.9	
Adjusted PAT	504	607	522	505	401	421	354	385	2,138	1,561	374	2.9
YoY change (%)	40.4	14.0	22.8	93.9	-20.5	-30.6	-32.2	-23.7	35.5	-27.0	-25.8	

Key performance indicators

Y/E March		FY22						
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Average growth in the last two years (%)								
Sales	3.2	8.1	4.5	1.6	12.9	11.7	13.9	18.9
EBITDA	15.9	10.2	6.6	11.2	1.2	-6.1	-0.8	27.6
PAT	25.7	15.7	5.3	16.3	10.0	-8.3	-4.7	35.1
As a percentage of sales								
COGS	54.1	52.5	51.7	54.9	56.9	60.3	59.0	59.9
Other expenditure	27.7	29.7	31.3	30.8	30.6	28.1	29.6	29.5
Depreciation	4.4	3.9	4.2	4.1	3.9	3.6	4.0	3.0
YoY change (%)								
COGS	7.8	4.0	13.8	26.6	28.1	32.9	28.5	20.3
Other expenditure	-9.4	11.7	14.0	14.6	34.9	9.5	6.3	5.8
Other income	-12.2	-27.7	18.6	19.6	14.2	33.0	-32.6	-12.8
EBIT	26.4	15.4	31.1	136.7	-25.4	-33.1	-34.1	-18.7

E: MOFSL estimates



Highlights from the management commentary

Financial highlights

- JYL has taken various price hikes in the range of 6-7% and has also reduced grammage. It has also taken a minor price increase in Apr'22.
- Input cost rose by 14%.
- The management stated that they have already taken four-to-five rounds of price hike in FY22 and hence the speed of price hikes going ahead will be moderate so that it does not negatively impact demand.
- Naphtha and soda ash has seen a sharp price increase and accounts for twothird of raw material in its entire product portfolio.
- The management will be focusing on SKU rationalization and better product mix.
- The management highlighted that it is experiencing stable consumer demand on a pan-India basis.
- Volume growth for 4Q/FY22 is 3.6/9%.
- LUP accounts for 30-35% of total product portfolio.

Channels and network

- There is a marginal decline in rural demand (40% of JYL's sales accrues from the rural market). The management expects potential rural offtake recovery on the back of a good monsoon
- The management highlighted that it will be adding more sales teams on the ground and would be focusing on increasing distribution reach in rural market.
- The company crossed direct reach of 1m outlets.

Products and categories:

- **Fabric care** Large packs across all channels are doing well and e-commerce business is growing by 30-35% yearly. This segment has taken 6-7% price hike during the year and the balance would be attributable to volume growth.
 - 'Ujala IDD' It commands 21.9% market share in Kerala, and priced at a premium rate to the benchmark. Pricing is at par with competition in other places.
- **Dish wash** Exo and Prill, both continue to do well. The company has conducted very strong distribution drives across channels for dish wash.
 - Exo seeing double-digit growth on the back of LUPs and also gaining new consumers. Exo bar has crossed INR5b in revenue.
 - Prill It witnessed a small market share loss.
- **HI-LV** Extreme weather conditions have impacted the key season of March-April. It recorded negative growth in coils while liquid vapor is doing well.
- **Personal care** Margo franchise doing well and also saw price hikes.

Going ahead

- Ujala IDD It was extended to Tamil Nadu (TN) and West Bengal (WB). TN is responding well and it's only been two-to-three months of launch in WB where management is expecting a good response.
- Crisp and Shine It was extended to AP and Telangana and the company is receiving a fairly good response. Now with schools and offices starting, management is seeing good traction in this space.
- The company will be looking at any M&A opportunities in the categories in which it is present in.

Key exhibits

Exhibit 1: Consolidated quarterly performance

exhibit 1: Consolidated quarterly performant			
Category sales (INR m)	4QFY21	3QFY22	4QFY22
Fabric Care	1,803	2091	2126
Dishwashing	1,692	2011	1898.2
Household Insecticides	872	514	792.7
Personal Care	418	530	467.2
Other products	166	244	183
Total	4,951	5,390	5,467
Category salience (%)			
Fabric Care	36.4	38.8	38.9
Dishwashing	34.2	37.3	34.7
Household Insecticides	17.6	9.5	14.5
Personal Care	8.4	9.8	8.5
Other products	3.4	4.5	3.3
Total	100.0	100.0	100.0
Category growth (%)			
Fabric Care	15.8	18.9	17.9
Dishwashing	33.2	10.5	12.2
Household Insecticides	35.8	9.8	(9.1)
Personal Care	38.4	0.2	11.7
Other products	5.3	28.9	10.1
Total	26.0	13.1	10.4
Category result (INR m)			
Fabric Care	330	319	252.1
Dishwashing	288	236	233.6
Household Insecticides	2	-40	3.3
Personal Care	71	73	59.5
Other products	-37	-20	-0.8
Total	654	567	548
Result salience (%)			
Fabric Care	50.4	56.2	46.0
Dishwashing	44.0	41.5	42.7
Household Insecticides	0.3	(7.1)	0.6
Personal Care	10.9	12.9	10.9
Other products	(5.6)	(3.6)	(0.1)
Total	100.0	100.0	100.0
EBIT margin (%)			
Fabric Care	18.0	(11.3)	(23.6)
Dishwashing	81.4	(35.0)	(18.9)
Household Insecticides	(102.8)	85.7	73.7
Personal Care	51.6	(31.6)	(16.3)
Other products	(16.2)	(46.3)	(97.8)
Total	75.5	(26.3)	(16.3)
	70.0	(20.0)	(2010)

Source: Company, MOFSL

Valuation and view

What has happened over the past 10 years?

- Given its size (INR6b/INR17.1b in FY10/FY20), which is much smaller v/s its peers, JYL's financial performance has been disappointing over the past 10 years.
- While it has reported ~11% sales CAGR over this period, EBITDA/PAT CAGR has been tepid (~11%/~8%).
- Sales/EBITDA/PAT CAGR at 2.5%/9%/5.5% for the last five years has not been much better.

- Growth has been restricted by: a) higher penetration and regional dependence of its largest brand Ujala, and b) limited success in terms of achieving profitable growth in other categories/geographies outside South India.
- The expiry of the Henkel option, which could have added more brands to its portfolio, has also been a setback.
- Given the above factors, it is not surprising that the stock has been an underperformer in recent years.

Our view on the stock

- We lower our FY23 EPS estimate by 7.9% on account of continued raw material pressure and our FY24 EPS estimate by less than 2%.
- For a company that has a far lower sales base of INR21.9b in FY22 (v/s peers), its performance over the past five years has been consistently lackluster (at 5.5%/-0.5% sales/operating profit CAGR).
- RoCE at 11% in FY22 remains far inferior v/s its peers. No marked uptick is visible over the medium term. We assign a 15x EV/EBITDA target multiple to our Mar'24E targets, resulting in a TP of INR150 per share. We maintain our Neutral rating.

Exhibit 2: Revise our FY23/FY24 EPS estimate by -7.9%/-1.8%

	New estimate		Old es	timate	Change (%)		
	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E	
Sales	24,381	26,548	23,268	25,341	4.8	4.8	
EBITDA	3,049	3,652	3,200	3,661	-4.7	-0.2	
PAT	1,883	2,319	2,045	2,362	-7.9	-1.8	







Exhibit 4: P/E ratio (x) for the Consumer sector



Source: Company, MOFSL Source: Company, MOFSL

 $Motilal\ Oswal$ Jyothy Laboratories

Financials and valuations

Consolidated Income Statement								(INR m)
Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
Total Income from Operations	16,830	16,724	18,136	17,112	19,091	21,965	24,381	26,548
Change (%)	5.7	-0.6	8.4	-5.6	11.6	15.1	11.0	8.9
Cost of Materials Consumed	8,941	8,753	9,707	9,009	10,104	12,830	14,137	15,065
As a percentage of Sales	53.2	52.3	53.5	52.6	52.9	58.4	58.0	56.7
Gross Profit	7,889	7,971	8,429	8,103	8,987	9,135	10,244	11,484
Margin (%)	46.9	47.7	46.5	47.4	47.1	41.6	42.0	43.3
Personnel Expenses	1,752	1,908	2,076	2,193	2,325	2,475	2,792	3,080
As a percentage of Sales	10.4	11.4	11.4	12.8	12.2	11.3	11.5	11.6
Other Expenses	3,591	3,488	3,542	3,398	3,517	4,178	4,403	4,752
As a percentage of Sales	21.4	20.9	19.5	19.9	18.4	19.0	18.1	17.9
Total Expenditure	14,285	14,149	15,325	14,601	15,946	19,483	21,332	22,897
As a percentage of Sales	85.0	84.6	84.5	85.3	83.5	88.7	87.5	86.2
EBITDA	2,545	2,575	2,811	2,511	3,145	2,482	3,049	3,652
Margin (%)	15.1	15.4	15.5	14.7	16.5	11.3	12.5	13.8
Depreciation	301	311	306	529	556	582	867	922
EBIT	2,245	2,263	2,505	1,982	2,589	1,901	2,182	2,730
Int. and Finance Charges	565	481	352	329	192	118	83	74
Other Income	107	625	278	203	185	187	197	208
PBT after EO Exp.	1,787	2,407	2,430	1,818	2,346	1,969	2,296	2,863
Current Tax	-255	619	454	189	440	378	413	544
Tax Rate (%)	-14.3	25.7	18.7	10.4	18.7	19.2	18.0	19.0
Less: Minority Interest	40	73	75	77	88	29	29	29
Adjusted PAT	2,042	1,789	1,976	1,667	2,142	1,591	1,883	2,319
Change (%)	176.6	-12.4	10.5	-15.6	28.5	-25.7	18.3	23.2
Consolidated Balance Sheet								(INR m)
Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
Equity Share Capital	182	182	367	367	367	367	367	367
Total Reserves	10,708	11,260	12,898	11,919	13,918	14,068	14,647	15,217
Net Worth	10,890	11,442	13,265	12,286	14,286	14,436	15,014	15,584
Minority Interest	-67	-139	-215	-291	-379	-407	-407	-407
Deferred Liabilities	-1,115	-902	-928	-1,027	-962	-907	-907	-907
Total Loans	4,983	5,441	2,809	2,830	1,169	1,265	596	596
Capital Employed	14,691	15,841	14,932	13,798	14,114	14,388	14,297	14,867
Gross Block	11,541	11,762	12,046	13,050	13,556	13,889	14,089	14,289
Less: Accum. Deprn.	571	855	1,040	1,558	2,089	2,670	3,538	4,460
Net Fixed Assets	10,970	10,907	11,006	11,492	11,467	11,218	10,551	9,829
Capital WIP	88	153	143	245	101	76	123	123
Total Investments	285	1,132	1,044	0	0	0	0	0

Deferred Liabilities	-1,115	-902	-928	-1,027	-962	-907	-907	-907
Total Loans	4,983	5,441	2,809	2,830	1,169	1,265	596	596
Capital Employed	14,691	15,841	14,932	13,798	14,114	14,388	14,297	14,867
Gross Block	11,541	11,762	12,046	13,050	13,556	13,889	14,089	14,289
Less: Accum. Deprn.	571	855	1,040	1,558	2,089	2,670	3,538	4,460
Net Fixed Assets	10,970	10,907	11,006	11,492	11,467	11,218	10,551	9,829
Capital WIP	88	153	143	245	101	76	123	123
Total Investments	285	1,132	1,044	0	0	0	0	0
Curr. Assets, Loans, and Adv.	6,073	6,695	6,301	5,598	7,029	8,027	9,123	11,260
Inventory	1,925	1,836	1,974	2,251	2,786	2,972	3,413	3,717
Account Receivables	1,228	1,674	1,534	1,224	944	1,431	1,219	1,327
Cash and Bank Balance	1,034	1,367	964	289	1,938	2,112	2,196	3,717
Loans and Advances and Others	1,886	1,818	1,830	1,834	1,361	1,512	2,294	2,498
Curr. Liability and Prov.	2,725	3,045	3,563	3,537	4,483	4,933	5,500	6,344
Account Payables	1,490	1,720	2,134	1,450	2,143	2,364	2,438	2,655
Other Current Liabilities	654	663	715	1,299	1,520	1,767	2,208	2,760
Provisions	581	663	715	788	820	802	853	929
Net Current Assets	3,348	3,650	2,738	2,061	2,546	3,094	3,623	4,916
Appl. of Funds	14,691	15,841	14,932	13,798	14,114	14,388	14,297	14,867

E: MOFSL estimates

Financials and valuations

Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
Basic (INR)								
EPS	5.6	4.9	5.4	4.5	5.8	4.3	5.1	6.3
Cash EPS	6.4	5.7	6.2	6.0	7.3	5.9	7.5	8.8
BV/Share	29.7	31.2	36.1	33.5	38.9	39.3	40.9	42.4
DPS	3.0	0.5	6.0	0.0	4.0	2.5	3.0	4.0
Payout (%)	64	12	134	0	83	70	71	77
Valuation (x)								
P/E	27.1	30.9	28.0	33.2	25.8	34.8	29.4	23.9
Cash P/E	23.6	26.4	24.3	25.2	20.5	25.5	20.1	17.1
P/BV	5.1	4.8	4.2	4.5	3.9	3.8	3.7	3.6
EV/Sales	1.8	1.8	3.1	3.4	2.9	2.5	2.2	2.0
EV/EBITDA	12.2	11.8	20.0	23.1	17.4	22.0	17.6	14.3
Dividend Yield (%)	2.0	0.3	4.0	0.0	2.7	1.7	2.0	2.7
FCF per share	5.9	13.6	7.2	3.5	10.3	4.9	5.3	8.5
Return Ratios (%)								
RoE	20.5	16.0	16.0	13.0	16.1	11.1	12.8	15.2
RoCE	18.3	13.1	13.7	12.6	14.7	10.8	12.5	15.0
RoIC	20.0	12.7	15.7	13.6	16.6	12.7	14.8	19.2
Working Capital Ratios								
Asset Turnover (x)	1.1	1.1	1.2	1.2	1.4	1.5	1.7	1.8
Debt/Equity ratio	0.5	0.5	0.2	0.2	0.1	0.1	0.0	0.0

Consolidated Cash Flow Statement								(INR m)
Y/E March	FY17	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
OP/(Loss) before Tax	1,787	2,407	2,430	1,815	2,346	1,969	2,296	2,863
Depreciation	301	311	306	529	556	582	867	922
Interest and Finance Charges	493	413	314	304	161	82	83	74
Other income	18	-409	-25	-21	232	-36	-197	-208
Direct Taxes Paid	-309	-251	-418	-386	-327	-313	-413	-544
(Inc.)/Dec. in WC	-656	-38	409	-527	1,055	-259	-445	229
CF from Operations incl. EO	1,633	2,434	3,016	1,715	4,022	2,025	2,191	3,337
(inc.)/dec. in FA	-567	43	-383	-415	-257	-214	-247	-200
(Pur.)/Sale of Investments	598	-807	112	1,061	0	0	0	0
Others	56	115	37	4	45	29	225	236
CF from Investments	87	-649	-234	650	-212	-185	-22	36
Issue of Shares	4,001	600	4	0	0	0	0	0
(Inc.)/Dec. in Debt	492	2,276	-610	41	-1,669	100	-669	0
Interest Paid	-1,555	-600	-342	-212	-281	-74	-83	-74
Dividend Paid	-181	-1,090	-182	-2,656	0	-1,469	-1,333	-1,777
Others	-4,054	-2,639	-2,055	-211	-212	-224	0	0
CF from Fin. Activity	-1,298	-1,453	-3,185	-3,039	-2,161	-1,667	-2,085	-1,852
Inc./Dec. in Cash	422	332	-403	-674	1,649	174	84	1,521
Opening Balance	612	1,034	1,367	964	289	1,938	2,112	2,196
Closing Balance	1,034	1,367	964	289	1,938	2,112	2,196	3,717

E: MOFSL estimates

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	<-10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.nseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated. from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company. MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

21 January 2022

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com.clin no.: L67190MH2005PLC153397.Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai-400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs,Insurance Products and IPOs.Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.